Welcome to our dedicated page for Lipocine news (Ticker: LPCN), a resource for investors and traders seeking the latest updates and insights on Lipocine stock.
Lipocine Inc. (NASDAQ: LPCN) is a biopharmaceutical company that publicly describes itself as leveraging a proprietary technology platform to develop therapeutics with effective oral delivery. News about Lipocine often centers on clinical trial milestones, regulatory interactions, and partnering activity related to its oral drug candidates.
A key focus of recent news is LPCN 1154, an oral formulation of brexanolone in development for the potential treatment of postpartum depression (PPD). Company press releases highlight the initiation of a pivotal Phase 3 trial, first patient dosing, enrollment progress, interim safety reviews by an independent Data Safety Monitoring Board, and plans to use Phase 3 data to support a 505(b)(2) NDA submission. Updates also describe the outpatient design of the trial and its target population of women with severe PPD.
News flow also covers LPCN 2401, an oral proprietary anabolic androgen receptor agonist being evaluated in obesity‑related settings. Lipocine has reported Phase 2 clinical data showing changes in body composition and liver‑related measures in men with obesity and metabolic dysfunction associated steatohepatitis, and has presented these data at the ObesityWeek meeting. Additional releases discuss regulatory status and development plans for proof‑of‑concept studies.
Other recurring topics include LPCN 2101 for the potential treatment of epilepsy, with announcements about abstract acceptances and poster presentations at the American Epilepsy Society annual meeting, as well as corporate updates on financial results, TLANDO licensing and royalty revenue, and participation in investor conferences. Investors and observers can use the LPCN news stream to follow clinical progress, safety updates, licensing developments, and strategic communications that the company files or references in its SEC reports.
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, announced the dismissal of a shareholder derivative action, Wajda v. Patel, et al., by Vice Chancellor Laster in Delaware on July 31, 2020. The suit, filed on February 15, 2019, against the company's board, was dismissed due to the plaintiff's failure to demonstrate demand futility as per Delaware Chancery Rule 23.1. This development allows Lipocine to move forward without the burden of this litigation.
Lipocine Inc. (NASDAQ: LPCN) announced on July 13, 2020, that it has regained compliance with Nasdaq's minimum bid price requirement, as confirmed by a Nasdaq letter dated July 9, 2020. This development affirms that the company meets the criteria outlined in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. This compliance is critical for Lipocine's operations and investor confidence, as it avoids potential delisting threats that could negatively impact stock performance.